Navigation Links
Toyota Tsusho America, Inc. and Nippon Kayaku Co., Ltd. Announce the Formation of GlycoMark, Inc., a Joint Venture to Develop and Commercialize Novel Biomarkers for Diabetes
Date:7/17/2008

GlycoMark(R) Blood Test Now Established to Provide Physicians with Vital

Information Missed by Hemoglobin A1c Test to More Effectively Manage

Patients with Diabetes

NEW YORK and WINSTON-SALEM, N.C., July 17 /PRNewswire/ -- Toyota Tsusho America, Inc. (New York, NY) and Nippon Kayaku Co., Ltd. (Tokyo, Japan) announced today the formation of a new joint venture company, GlycoMark, Inc., dedicated to the discovery and commercialization of novel biomarkers for diabetes. The company is located in New York, NY and the Piedmont Triad Research Park in Winston-Salem, NC.

Toyota Tsusho America, Inc., Nippon Kayaku Co., Ltd., and the BioMarker Group (Kannapolis, NC) have worked together as partners to commercialize the GlycoMark(R) diabetes blood test over the past few years prior to establishing the new company. With increasing clinical acceptance and commercial success of the GlycoMark(R) blood test, a solid foundation has now been built to position GlycoMark, Inc. as a leader in the field of diabetes diagnostics.

"The GlycoMark(R) blood test is being increasingly utilized in clinical practice to manage patients with diabetes and in clinical drug studies," said John Buse, MD, PhD, director of the diabetes care center at the University of North Carolina School of Medicine, Chapel Hill. "The test is particularly useful in monitoring moderately controlled patients, where GlycoMark may be more dynamic than the gold standard hemoglobin A1C test in reflecting glucose levels, according to some recent studies."

"I am excited about the vision for this new company," said Eric Button, president and co-owner of GlycoMark, Inc. "We have already achieved several key clinical and commercialization milestones for GlycoMark(R) and the success of the test has put us in a strong position to transform testing for diabetes, a near-epidemic in the U.S. and worldwide."

GlycoMark(R) milestones include:

-- FDA approval

-- Establishment in diabetes care through numerous research publications in leading medical journals

-- Featured as a premier diagnostic test by Quest Diagnostics and LabCorp. Available at these and other prominent national medical reference laboratories.

-- Highlighted as an American Diabetes Association sponsored symposium at its 2008 annual meeting.

-- Recent study by Eli Lilly of over 2000 patients from eleven countries indicates that GlycoMark(R) reflects glycemia better than the current gold standard, Hemoglobin A1c, in moderately controlled diabetic patients.

-- GlycoMark(R) is best marker for efficacy for blockbuster drugs Byetta (Amylin/Lilly) and Januvia (Merck) in moderately controlled patients.

-- Inclusion in the International Diabetes Federation (IDF) Global Diabetes Care Guidelines.

-- Establishment of a scientific advisory board comprised of leading diabetologists worldwide.

The new company will focus initially on the continued commercialization of the GlycoMark(R) laboratory test with partner reference laboratories in the U.S. Preparations are currently underway for introduction of GlycoMark(R) internationally, including the European Union. The new joint venture company is also developing a point-of-care and home-test version of the GlycoMark(R) test.

About GlycoMark Blood Test

GlycoMark(R) is an FDA-approved test for monitoring intermediate glycemic control by measuring the levels of a monosaccharide 1,5-anhydroglucitol (1,5-AG) in blood. Multiple published studies in peer-reviewed journals have shown that the 1,5-AG test is a specific index of postprandial hyperglycemia (elevated after-meal glucose levels) and short-term glycemic control -- providing a useful complement to A1C testing. GlycoMark(R) is being used in clinical practices nationwide and is available at major reference laboratories including Quest Diagnostics, LabCorp, Esoterix, Mayo Medical Laboratories, ARUP Laboratories, and Specialty Laboratories. The test is also available at most major contract research organizations for pharmaceutical research studies.

About Toyota Tsusho America, Inc.

Toyota Tsusho America, Inc. has emerged in the US market as a multi-business entity with expanded capabilities, fresh ideas, and a greatly broadened experience base. Toyota Tsusho America, Inc.'s seven operating divisions (Chemicals, Metals, Machinery & Electronics, Logistics, Automotive, Food, and Consumer Products) pursue a broad range of activities which combine international trading functions with domestic source and supply activities, supply chain and logistics services, and processing and manufacturing functions in both the industrial and consumer sectors.

About Nippon Kayaku Co., Ltd.

Nippon Kayaku Co., Ltd. is a comprehensive fine chemical manufacturer, which had been established in Japan in 1916 and has continued to expand into a broad range of new fields including explosives, dyes, pharmaceuticals, in-vitro diagnostics, agrochemicals, functional products, catalysts, and automobile safety parts. Our products are distributed worldwide now. Nippon Kayaku Co., Ltd. pursues to serve customers in global niche markets with innovative products through a fusion of technology and human resources.


'/>"/>
SOURCE GlycoMark, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Nautica Malibu Triathlon Presented by Toyota Raises $718,000 for Childrens Hospital Los Angeles Pediatric Cancer Research
2. 100 Black Men of America, Inc. and American Red Cross Sign National Agreement to Increase Diverse Outreach Nationwide
3. Coalition America, Inc. Again Named One of Georgias Fastest Growing Technology Companies in Deloittes Technology Fast 50 Program
4. Ambulatory Services of America, Inc. Announces Joint Venture with Southern Ocean County Radiation Oncology, LLC
5. Michael D. Farley Appointed Chief Operating Officer of Lupus Foundation of America, Inc.
6. Ambulatory Services of America, Inc. Announces Joint Venture With Denton Cancer Center, LP
7. Ambulatory Services of America, Inc. Announces Investment by Lindsay Goldberg
8. Ambulatory Services of America, Inc. Announces Joint Venture to Operate Radiation Oncology Facility in Dallas, Texas
9. Ambulatory Services of America, Inc. Announces Joint Venture to Operate Chicago-Area Radiation Oncology Facility
10. Ambulatory Services of America, Inc. Announces the Acquisition of Dialysis Operations in St. Louis, Missouri
11. National Non-Profit, EyeCare America, and the Maryland Society of Eye Physicians & Surgeons Host Finish Line Celebration for “EyeRide for Sight” Cyclists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
Breaking Medicine Technology: